Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Clinical Genitourinary Cancer|December 31, 2024
A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE)Michael Staehler, Umberto Basso, Jean-Christophe Eymard, et al.
The New England Journal of Medicine|October 1, 2019
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate CancerRonald de Wit, Johann de Bono, Cora N Sternberg, et al.
European Journal of Cancer (Oxford, England : 1990)|April 12, 2018
Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancerConstance Thibault, Jean-Christophe Eymard, Alison Birtle, et al.
The Oncologist|May 22, 2012
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trialBruno Coudert, Bernard Asselain, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trialCora N Sternberg, Daniel P Petrylak, Oliver Sartor, et al.
Breast Cancer Research and Treatment|March 29, 2023
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trialsElie Rassy, Thomas Filleron, Alessandro Viansone, et al.
Breast Cancer (Tokyo, Japan)|January 11, 2023
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohortLaetitia Collet, Lauriane Eberst, Gauthier Ludovic, et al.
European Urology|July 18, 2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD StudyCora N Sternberg, Daniel Castellano, Johann de Bono, et al.
The Lancet. Oncology|December 3, 2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trialKarim Fizazi, Lance Pagliaro, Agnes Laplanche, et al.
European Urology Oncology|October 24, 2024
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line TreatmentPhilippe Barthélémy, Constance Thibault, Aude Fléchon, et al.
Pageof 7